Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Noopur Raje, M.D.

Co-Author

Back to Details
This page shows the publications co-authored by Noopur Raje and Steven Treon.
Noopur Raje
Connection Strength
1.207
Steven Treon
  1. Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemia. Leukemia. 2021 Sep 16.
    View in: PubMed
    Score: 0.247
  2. Ibrutinib Monotherapy in Symptomatic, Treatment-Naïve Patients With Waldenström Macroglobulinemia. J Clin Oncol. 2018 09 20; 36(27):2755-2761.
    View in: PubMed
    Score: 0.198
  3. Tumour cell/dendritic cell fusions as a vaccination strategy for multiple myeloma. Br J Haematol. 2004 May; 125(3):343-52.
    View in: PubMed
    Score: 0.074
  4. Elevated soluble MUC1 levels and decreased anti-MUC1 antibody levels in patients with multiple myeloma. Blood. 2000 Nov 01; 96(9):3147-53.
    View in: PubMed
    Score: 0.058
  5. Immunotherapeutic strategies for the treatment of plasma cell malignancies. Semin Oncol. 2000 Oct; 27(5):598-613.
    View in: PubMed
    Score: 0.058
  6. Kaposi's sarcoma-associated herpesvirus gene sequences are detectable at low copy number in primary amyloidosis. Amyloid. 2000 Jun; 7(2):126-32.
    View in: PubMed
    Score: 0.056
  7. Bone marrow and peripheral blood dendritic cells from patients with multiple myeloma are phenotypically and functionally normal despite the detection of Kaposi's sarcoma herpesvirus gene sequences. Blood. 1999 Mar 01; 93(5):1487-95.
    View in: PubMed
    Score: 0.052
  8. Muc-1 core protein is expressed on multiple myeloma cells and is induced by dexamethasone. Blood. 1999 Feb 15; 93(4):1287-98.
    View in: PubMed
    Score: 0.052
  9. Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017 02; 15(2):230-269.
    View in: PubMed
    Score: 0.045
  10. NCCN Guidelines Insights: Multiple Myeloma, Version 3.2016. J Natl Compr Canc Netw. 2016 04; 14(4):389-400.
    View in: PubMed
    Score: 0.042
  11. Multiple Myeloma, Version 2.2016: Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2015 Nov; 13(11):1398-435.
    View in: PubMed
    Score: 0.041
  12. Multiple myeloma, version 1.2013. J Natl Compr Canc Netw. 2013 Jan 01; 11(1):11-7.
    View in: PubMed
    Score: 0.034
  13. Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma, version 2.2013. J Natl Compr Canc Netw. 2012 Oct 01; 10(10):1211-9.
    View in: PubMed
    Score: 0.033
  14. Multiple myeloma. J Natl Compr Canc Netw. 2011 Oct; 9(10):1146-83.
    View in: PubMed
    Score: 0.031
  15. Conflicts of interest, authorship, and disclosures in industry-related scientific publications. Mayo Clin Proc. 2010 Feb; 85(2):197-9; author reply 201-4.
    View in: PubMed
    Score: 0.028
  16. Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application. Br J Haematol. 2005 Jan; 128(2):192-203.
    View in: PubMed
    Score: 0.019
  17. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood. 2001 Jul 01; 98(1):210-6.
    View in: PubMed
    Score: 0.015
  18. Ku86 variant expression and function in multiple myeloma cells is associated with increased sensitivity to DNA damage. J Immunol. 2000 Dec 01; 165(11):6347-55.
    View in: PubMed
    Score: 0.015
  19. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood. 2000 Nov 01; 96(9):2943-50.
    View in: PubMed
    Score: 0.015
  20. SHP2 mediates the protective effect of interleukin-6 against dexamethasone-induced apoptosis in multiple myeloma cells. J Biol Chem. 2000 Sep 08; 275(36):27845-50.
    View in: PubMed
    Score: 0.014
  21. Characterization of signaling cascades triggered by human interleukin-6 versus Kaposi's sarcoma-associated herpes virus-encoded viral interleukin 6. Clin Cancer Res. 2000 Mar; 6(3):1180-9.
    View in: PubMed
    Score: 0.014
  22. Isolation and characterization of human multiple myeloma cell enriched populations. J Immunol Methods. 2000 Feb 21; 235(1-2):11-9.
    View in: PubMed
    Score: 0.014
  23. CD40 activation mediates p53-dependent cell cycle regulation in human multiple myeloma cell lines. Blood. 2000 Feb 01; 95(3):1039-46.
    View in: PubMed
    Score: 0.014
  24. RAFTK/PYK2-dependent and -independent apoptosis in multiple myeloma cells. Oncogene. 1999 Nov 18; 18(48):6733-40.
    View in: PubMed
    Score: 0.014
  25. Functional interaction between retinoblastoma protein and stress-activated protein kinase in multiple myeloma cells. Cancer Res. 1999 Mar 15; 59(6):1192-5.
    View in: PubMed
    Score: 0.013
  26. Detection of Kaposi's sarcoma herpesvirus DNA sequences in multiple myeloma bone marrow stromal cells. Blood. 1999 Mar 01; 93(5):1482-6.
    View in: PubMed
    Score: 0.013
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
© 2021 President and Fellows of Harvard College
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.